The Ministry of Health of Russia has registered an anticancer drug developed in Cuba for use in specific oncology treatments, an authorization that opens a new regulatory pathway for Cuban biotechnology in the Russian pharmaceutical market.
The product, commercially named Nimolancim (Нимоланцим®), contains as its active ingredient nimotuzumab, a monoclonal antibody produced by the Center for Molecular Immunology (CIM), based in Havana, as stated in the State Register of Medicines of Russia (GRLS).
The authorization was granted on October 6, 2026, valid until October 6, 2031, according to the registration certificate ЛП-№(016793)-(РГ-RU) (official drug registration number in Russia).
The announcement was made public on October 15, when the Russian agency Interfax reported, citing the Ministry of Health of Russia, about the inclusion of the drug in the national pharmaceutical register.
According to the ministerial information released by Interfax, the product is intended for the treatment of adult patients with certain malignant tumors, including some of the esophagus, head and neck, as well as certain brain tumors.
The authorization corresponds to specific oncological indications and does not mean that the medication can be used interchangeably against any type of cancer.
The Russian Ministry presented the registration as an expansion of the targeted therapy options available for oncological practice in the country.
The nimotuzumab belongs to the group of monoclonal antibodies and acts on the epidermal growth factor receptor, known by its English acronym as EGFR.
This receptor is involved in processes related to cell growth and multiplication. Its activity can be altered in certain types of tumors, making it one of the targets used in targeted oncology treatments.
The Cuban medication is classified in the Russian registry as an EGFR inhibitor, within the pharmacotherapeutic group of antineoplastic agents.
It is not a cancer vaccine, but a medication based on a monoclonal antibody that is administered through infusion.
The authorized presentation consists of a concentrate of 5 milligrams per milliliter (5 mg/ml) for preparing a solution intended for intravenous infusion.
The register includes 10 milliliter vials, packaged in sets of four, and stipulates that the product must be stored between 2 and 8 degrees Celsius, protected from light and must not be frozen.
The declared shelf life for the finished medication is three years, under the specified storage conditions.
One of the most important aspects of the registry is the identification of the companies and institutions involved in its production.
The Russian company AO Lancet (АО «Ланцет») appears as the holder of the registration certificate, identifying it as the entity responsible for the drug's authorization in Russia.
However, the register explicitly distinguishes between administrative ownership and the different stages of manufacturing.
The Center for Molecular Immunology in Havana appears as the manufacturer of the pharmaceutical substance and the finished medicine, in addition to participating in primary packaging, other conditioning phases, and quality control activities.
On its part, the Russian company AO Biokhimik, located in Saransk, Republic of Mordovia, is among the entities responsible for secondary and tertiary packaging, as well as quality control for product release.
The documentation reflects, therefore, a production chain in which the Cuban institution retains fundamental responsibilities for manufacturing, while Russian companies take on specific regulatory and industrial functions.
Interfax precisely reported this distribution of responsibilities, noting that the medication is produced through international cooperation with the Cuban Center for Molecular Immunology.
The Russian Ministry of Health also identified Biokhimik as a participant in secondary conditioning and final quality control.
However, the registry does not provide information on the quantities that will be manufactured or sent to Russia, nor does it specify the price of the product or the economic conditions of the agreements between the involved entities.
It also does not allow for an estimate of how much money Cuba could earn from the potential commercialization of the medication.
The health authorization is an important regulatory requirement, but by itself, it does not confirm that sales have begun, that the product is available in Russian hospitals, or that there are already executed supply contracts.
Similarly, the Russian registration does not imply automatic approval to market the drug in other markets, such as the United States or the European Union, where there are independent regulatory procedures.
The nimotuzumab is part of the research and development journey of the Molecular Immunology Center, a Cuban institution specialized in biotechnological products and treatments based on monoclonal antibodies.
Its incorporation into the Russian registry occurs against a backdrop of rapprochement between both countries in the pharmaceutical and biotechnological fields.
In June, Cuba and Russia announced a memorandum of understanding to jointly develop cancer vaccines during the St. Petersburg International Economic Forum.
The Russian Deputy Prime Minister Dmitry Chernishenko then explained that the cooperation would include projects related to oncology treatments and recalled that Russia had previously supplied substances intended for the production of medications in Cuba.
That memorandum contemplated the joint development of therapeutic vaccines against cancer, a line of research distinct from nimotuzumab, which is a monoclonal antibody and already has a background in pharmaceutical development.
Related videos:
Filed under: